The elimination of gentamicin-resistant gram-negative bacteria in a newborn intensive care unit

Infection. Jan-Feb 1987;15(1):32-4. doi: 10.1007/BF01646115.


The aminoglycosides play a central role in the treatment of infectious diseases caused by gram-negative bacteria. During the period of January to June 1984, 45 clinical specimens collected in our neonatal intensive care unit grew Enterobacter cloacae; 41 of them were gentamicin resistant. One neonate developed septicemia. The routine antibiotic protocol was then changed from gentamicin-ampicillin to amikacin-ampicillin for a period of six months. During this period the resistance to gentamicin declined to a minimum. Only eight of 122 specimens proved to harbor gram-negative organisms resistant to gentamicin. The gentamicin-resistant E. cloacae vanished. No isolate was resistant to amikacin. The gentamicin-ampicillin regimen was then reintroduced.

MeSH terms

  • Amikacin / therapeutic use
  • Ampicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Cross Infection / drug therapy*
  • Drug Therapy, Combination
  • Enterobacter / drug effects
  • Enterobacteriaceae Infections / drug therapy*
  • Gentamicins / therapeutic use*
  • Humans
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Penicillin Resistance
  • Sepsis / drug therapy


  • Anti-Bacterial Agents
  • Gentamicins
  • Ampicillin
  • Amikacin